Plus Therapeutics Inc (PSTV) USD0.001
Sell:$0.98Buy:$1.04
$0.07
(7.36%)
- This stock can be held in a
Stocks and Shares ISA$0.07
(7.36%)$0.07
(7.36%)Company Information
About this company
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Key people
Key facts
- EPICPSTV
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS72941H5090
- Market cap$5.60m
- Employees20
- Shares in issue17.26m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.